Trial · NCT01691898
Adverse events1,596
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,596
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 9 | 63 | |
| other | Anaemia | Blood and lymphatic system disorders | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 10 | 59 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort C (FL): RTX + Polatuzumab | 1 | 20 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | 2 | 9 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 4 | 40 | |
| other | Anaemia | Blood and lymphatic system disorders | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 4 | 40 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 0 | 63 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 1 | 59 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Cohort C (FL): RTX + Polatuzumab | 1 | 20 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | 0 | 9 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 2 | 40 | |
| other | Lymphadenopathy | Blood and lymphatic system disorders | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 0 | 40 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 19 | 63 | |
| other | Neutropenia | Blood and lymphatic system disorders | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 15 | 59 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort C (FL): RTX + Polatuzumab | 8 | 20 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort E (FL+DLBCL): Obinutuzumab + Polatuzumab | 4 | 9 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort G (Expansion, FL): Obinutuzumab + Polatuzumab | 8 | 40 | |
| other | Neutropenia | Blood and lymphatic system disorders | Cohort H (Expansion, DLBCL): Obinutuzumab + Polatuzumab | 8 | 40 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm A (FL+DLBCL): RTX+Pinatuzumab,Then RTX+Polatuzumab | 3 | 63 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | Arm B (FL+DLBCL): RTX+Polatuzumab,Then RTX+Pinatuzumab | 2 | 59 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01691898/events